All these results present new opportunities to evaluate the use of CD4+ T cell immunity as a powerful predictor, even more powerful than the use of CD8+ T cell immunity, of responders with multiple tumor types receiving immunotherapy. The gene discussed is CD8A; the disease is neoplasm.